GRCL: Gracell Bio Company Projected Revenue

Gracell Biotechnologies operates in the oncology sector, where demand for treatment remains independent of economic cycles. Revenues are based on insurance reimbursements for innovative CAR-T therapy. The current future sales metric for the company on GURU.Markets captures forecast dynamics, where the 0.00 mark records this indicator. Development relies on the implementation of automated bioreactors to eliminate defects during drug production.

Gracell - GRCL Company Future Revenue (period 07/04/2022 - 03/03/2024)

Summary analytical data breakdowns for Gracell (GRCL)

- stock value and consensus price forecast:

Price Chart Gracell Biotechnologies Inc.|GRCL - Price Target Chart

- market capitalization information:

Market Value Gracell|GRCL - Total Company Value

- balance sheet equity data:

Accounting Value per Share Gracell Biotechnologies|GRCL - Accounting Value of Company|Market Capitalization to Book Value Ratio gracellbio.com|GRCL - Company Balance Sheet Assets

- debt obligations and liquidity statistics:

- financial results and valuation multiples details:

GRCL - Profit After Payment of Taxes|Projected Future Earnings Gracell Biotechnologies|GRCL - Company Value to Net Income|Forward P/E Multiple gracellbio.com|GRCL - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Gracell Biotechnologies|GRCL - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Gracell Biotechnologies|GRCL - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months gracellbio.com|GRCL - Earnings per share trend in current year|Expected earnings per share growth for next year Gracell Biotechnologies

- sales volume and revenue information:

GRCL - Company Total Revenue|Projected Sales Volume gracellbio.com|GRCL - Price-to-Revenue Multiple|Price-to-Projected Revenue Ratio Gracell Biotechnologies|GRCL - Revenue Dynamics YoY (Last Twelve Months)

Summary company analytics:Gracell

The Gracell Biotechnologies (GRCL) chart reflects the commercialization potential of CAR-T therapy through the lens of projected sales revenue. This indicator aggregates forecasted capital flows, determining the fundamental business value based on expected demand. The metric's dynamics are sensitive to the success of the FasTCAR platform and its integration into the AstraZeneca structure. Growth in this indicator signals the scaling of leukemia treatment, confirming the long-term sustainability of the asset.

Competitors of Gracell Biotechnologies (GRCL)

Company Projected Revenue Legend Biotech Corporation (LEGN)|Company Projected Revenue SANA (Sana Biotechnology Inc)|Company Projected Revenue Autolus Pharma AUTL|Allogene Therapeutics - Company Projected Revenue|RNAC: Company Future Sales Volume|Company Future Revenue CLLS (cellectis.com)|CRBU: Projected Sales Volume|Company Expected Sales Volume Instil Bio Inc. (TIL)|GNTA (Genenta Science SpA) - Projected Sales Volume|Company Expected Sales Volume centurytx.com IPSC|Company Projected Revenue Jasper Bio (JSPR)|Senti Biosciences - Company Revenue Forecast|Projected Sales Volume ADAP (Adaptimmune Therapeutics)|cero.bio (CERO) - Company Expected Sales Volume|TCRT: Company Future Sales Volume|Company Future Revenue ACHL (Achilles Therapeutics PLC)|CRGX (Cargo Therapeutics) - Company Future Sales Volume|PSTX: Company Projected Revenue Volume|TSVT (2seventy bio) - Projected Sales Volume